Mayinglong subsidiary secures drug registration certificate

Mayinglong Pharmaceutical Group (SSE:600993) announced that its wholly-owned subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical, has been granted a drug registration certificate from the National Medical Products Administration for its Sodium Hyaluronate Eye Drops [Specification: 0.3% (0.4ml:1.2mg)]. The drug is classified as a Class 4 chemical drug, with registration number YBH12122025, and is indicated for corneal and conjunctival epithelial damage associated with conditions like dry eye syndrome and post-operative inflammation. According to Minenet data, the domestic market for Sodium Hyaluronate Eye Drops reached CNY15.93 million in 2023. Mayinglong stated that it had invested CNY461.47 million in research and development for this eye drop product. The company believes this approval will enhance its ophthalmology product line and market competitiveness, while also cautioning investors about market uncertainties. The announcement was made on June 10, 2025.